読み込み中
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
前日終値
$112.79
+$0.04 · +0.04%
市場前
$114.99
+$2.20 · +1.95%
10月12日 4:10 ET
日中の時刻はETです。市場データは遅延する場合があります。
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
日中レンジ
現在 $112.79
52週レンジ
現在 $112.79
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
97
大幅な割安
センチメント
73
強気
リスク
29
中程度のリスク
モメンタム
62
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
日中レンジ
現在 $112.79
52週レンジ
現在 $112.79
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 51.41億 USD | 42.41億 USD | 36.96億 USD | 33.95億 USD | 29.86億 USD |
| 売上原価 | 3.72億 USD | 3.12億 USD | 2.55億 USD | 2.07億 USD | 1.51億 USD |
| 粗利益 | 47.69億 USD | 39.29億 USD | 34.41億 USD | 31.88億 USD | 28.35億 USD |
| 研究開発 | 20.5億 USD | 26.07億 USD | 16.28億 USD | 15.86億 USD | 14.58億 USD |
| 販売・一般管理 | 13.76億 USD | 12.22億 USD | 11.56億 USD | 10.02億 USD | 7.4億 USD |
| 営業費用 | 34.26億 USD | 38.28億 USD | 27.85億 USD | 25.96億 USD | 22.49億 USD |
| 受取利息 | 1.06億 USD | 1.29億 USD | — | — | — |
| 支払利息 | 242.8万 USD | 228万 USD | 255.1万 USD | 266.6万 USD | 190.8万 USD |
| 減価償却費と償却費 | 9328.6万 USD | 8924.8万 USD | 8266万 USD | 6785.5万 USD | 5784.4万 USD |
| 営業利益 | 13.43億 USD | 1.01億 USD | 6.55億 USD | 5.92億 USD | 5.86億 USD |
| 純利益 | 12.87億 USD | 3261.5万 USD | 5.98億 USD | 3.41億 USD | 9.49億 USD |
会社概要が更新されました 2026年10月12日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P 500 ETF1557.T370.99億0.03%129.43兆 JPY0.09%￥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI6.66億0.03%2.3兆 USD0.03%$381.94+0.63%
Vanguard S&P 500 ETFVOO5.49億0.03%1.8兆 USD0.03%$715.59+0.61%
Vanguard Morningstar Small-Cap ETFVB4.81億0.26%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK2.76億0.60%447億 USD0.05%$344.74+1.22%
iShares Core S&P 500 ETFIVV2.55億0.03%8964.4億 USD0.03%$781.97+0.60%
State Street SPDR S&P 500 ETFSPY2.34億0.03%8172億 USD0.09%$778.57+0.60%
Invesco S&P 500 Equal Weight ETFRSP1.76億0.18%977.83億 USD0.20%$213.04+0.55%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYInvesco S&P 500 Equal Weight ETFRSPAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
